Dossier
Ipsen
Coverage of Ipsen in the Nexus archive.
- Ipsen is acquiring a Swiss biotech for up to $800 million to treat kidney transplant infections
Ipsen, a French drugmaker, is acquiring Swiss biotech Memo for up to $800 million. The upfront payment is 200 million euros, targeting a kidney transplant infection with no approved treatments.
- Ipsen is buying U.S. blood cancer startup Kartos for up to $1.75 billion
Ipsen, a French drugmaker, is acquiring U.S. blood cancer startup Kartos for up to $1.75 billion, with a $450 million upfront payment. Kartos is developing a late-stage drug for myelofibrosis.